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Introduction
The neurohormone melatonin (Figure 1 ) was discovered and characterized as N-acetyl-5methoxytryptamine more than fifty years ago by Aaron Lerner. 1 Its biosynthetic route was then established starting from the L-tryptophan acid following a circadian rhythm with high plasmatic concentration at night and low circulating levels during the day time. Melatonin is mainly secreted in humans by the pineal gland located in the hypothalamic suprachiasmatic nucleus (SCN), 2 but it is also synthesized by other regions of the CNS and by other tissues and cells such as the retina, 3 skin, bone marrow, lymphocytes, 4 and gastrointestinal tract. 5 Melatonin seems to play a major role in various physiological processes including, modulation of hormones secretion, 6 regulation of sleep-wake cycle 7 and cardiovascular functions, 8 pain perception, 9 immune system and core body temperature control. 10 Furthermore, melatonin was shown to be involved in several pathological processes such as sleep disturbances and insomnia, 11 cancer and inflammation, 12 neurodegenerative diseases, 13 diabetes, 14 depression and anxiety. 15 The endogenous role and mechanism of action of melatonin have not yet been fully elucidated.
The therapeutic potential of melatonin and most of its physiological effects are mainly mediated via activation of two of its receptors belonging to the superfamily of G-proteincoupled receptors (GPCRs) and named MT 1 and MT 2 . Both MT 1 and MT 2 have been cloned revealing that these two receptors are coupled to G αi proteins . 16 These receptors exhibit a sub-nanomolar binding affinity for melatonin. 17 A third binding site of melatonin named MT 3 was characterized as the human quinone reductase 2 and displays a low binding affinity for melatonin. 18 Later it was shown that these three melatoninergic binding sites were localized in different compartments of the human body. 19 In the central nervous system in SCN, cortex, pars tuberalis, 20 and peripherally in kidney, adipocytes, retina, blood vessels, gut, testes, bone marrow cells and human lymphocytes among others. 21 In order to provide a better understanding of the melatoninergic system and its physiological roles, during the last decades, much of the research was focused on the discovery of new analogs of melatonin. Moreover, the characterization of melatonin receptor-mediated functions requires potent and selective ligands for MT 1 and MT 2 . Nowadays, a lot of work has been done in this area, 22 however despite the large number of high affinity non-selective ligands, pronounced receptor subtype selective ligands especially for MT 1 remain a real challenge. Accordingly, after more than fifty years of research only few melatoninergic compounds are marketed or under clinical trials. Hence, circadin, ramelteon, agomelatine and tasimelteon constitute the only melatonin analogs that are commercialized up to now ( Figure   1 ). 23 For decades, our lab was involved in a large research program that consists in the pharmacomodulation of melatonin by replacing the indole scaffold by different bioisostere nucleus such as benzofurane, benzothiophene, isoquinoline, phthalazine, and naphthalene among others. In parallel, other modulations targeting different positions of the aromatic nucleus, the lateral acetamide chain and the methoxy group were performed. 24, 25 The substitution of the indole of melatonin with naphthalene and benzofurane nucleus was of major interest. First, agomelatine, the naphthalenic analogue of melatonin has showed a very good binding affinity at both MT 1 and MT 2 . Furthermore, this ligand is the only of the bioisosteric analogues of melatonin owning a serotonergic 5-HT 2C binding affinity. Secondly, the benzofuran analogue of melatonin, the N-acetyl-2- (5-methoxybenzo[b] furan- 3-yl) ethylamine (Chart 1), is a good ligand for the melatonin receptors and is metabolically more stable than melatonin. 26 In order to study the effect of the fusion of these two scaffolds on both the melatoninergic affinity and activity, herein, we report the synthesis and pharmacological evaluation of a new series of naphthofuranic derivatives as new MT 1 /MT 2 ligands. The new obtained naphthofuranic derivatives were then submitted to a series of additional modulations applied to the lateral chain and the acetamide function (Chart 1). We report hereafter the synthetic strategies and biological results of the prepared compounds.
Results and discussion
2.1. Chemistry. The synthetic strategy applied in order to prepare key amines 3 and 6 is shown in scheme 1 starting from 7-methoxy-beta-naphthol. Hence, two main routes were performed starting from the acid 1 issued from the condensation of 7-methoxynaphthol with ethyl 4-chloro-3-oxobutanoate in sulfuric acid according to the Pechmann procedure 27 followed by the transformation of the resulted chromenone into naphthofuranic derivative 1 by treatment with sodium hydroxide. 28a Route 1 consists of azide 2 preparation from 1 by treatment with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) (EDCI) and sodium azide.
Submission of the azide 2 to a Curtius rearrangement 28b led to the corresponding isocyanate; this non isolated intermediate was subsequently hydrolysed under acid conditions to provide the desired amine 3. In route 2, the acid 1 was first converted into amide 4 via treatment with oxalyl chloride and aqueous ammonia. Dehydration of 4 through treatment by trifluoroacetic anhydride (TFAA) led to nitrile 5. Chemical reduction of compound 5 using lithium aluminum hydride and aluminum chloride yielded amine 6 in good yield. In Scheme 2 is outlined the synthetic sequence used for the preparation of amines 10 and 15.
First, formylation of 2,7-dimethoxynaphthalene according to Vilsmeier-Haack conditions furnished aldehyde 7. 29 Selective demethylation via aluminum chloride treatment of the 2methoxy resulted into naphthol 7. O-alkylation of this later compound with the appropriate alkyl bromide in the presence of potassium carbonate led to derivatives 8 and 11. Submission of 8 and 11 to a base-catalysed cyclisation reaction led to naphthofuranic derivatives 9 and 12.
Reduction of the ester 12 by treatment with lithium aluminum hydride provided the alcohol 13. Activation of compound 13 with thionyl chloride in the presence of pyridine followed by nucleophilic substitution with sodium cyanide gave the nitrile 14 in a good yield. Finally, chemical reduction of nitriles 9 and 14, by a mixture of lithium aluminum hydride and aluminum chloride gave the desired amines 10 and 15. 
Pharmacology
In this paper, we describe the design and synthesis of a new series of naphthofuranic derivatives as melatonin MT 1 and MT 2 ligands. The new synthesized derivatives are composed of two position isomers, differently substituted at position 1 or 2 of the naphthofuranic nucleus. To determine their binding affinities and functional activities, the synthesized compounds were assayed at human MT 1 and MT 2 melatonin receptors stably transfected in Chinese Hamster Ovarian (CHO) cells, using 2-[ 125 I]iodomelatonin as radioligand. 32 In tables 1-2, are shown the chemical structures and obtained biological results.
Results and Discussion.
The binding affinity results of the prepared acetamides 3a and 6a revealed that this type of structure owns a good melatoninergic binding affinity at both MT 1 and MT 2 receptors, and a very good affinity at MT 2 with regard to both melatonin and agomelatine (Table 1) . Particularly, compound 6a exhibits an excellent binding affinity and a selectivity of 31 fold to MT 2 receptor subtype than to MT 1 . Modulation of the acetamide group of both 3a and 6a has led to the synthesis of cyclopropanamides (3b, 6b), isopropylamide (3c), and fluoroacetamide (3d) derivatives with lower binding affinity at both MT 1 and MT 2 . Similarly, substitution of the acetamide by an ethylurea (6c) produced the decrease of the melatoninergic binding affinity. Furthermore and in order to fine tune the effect of the lateral chain position on the melatoninergic binding affinity, compounds 10a and 15a, isomers of 3a and 6a, were synthesized and biologically evaluated. From the obtained results (Table 1) , we can conclude that the lateral chain displacement from position 1 to 2 in this naphthofuranic series has no effect on the binding affinity at MT 1 and MT 2 . Interestingly, replacement of the acetamide group by bulky amides (10b, 15b) and fluoroacetamide (10c) in 
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Compound 16; 24] (2) 15 [14; 17] (2) Finally, with regard to the agomelatine profile, the prepared compounds were tested for their binding affinities at serotonin 5-HT 2C receptor subtype and revealed a binding affinity at the micromolar range for most of the compounds (data not shown). 
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Conclusions
In conclusion we report herein the synthesis and binding affinity results of new series of naphthofuran derivatives as melatonin ligands. Besides acetamides showed good binding affinities at both MT 1 and MT 2 receptor subtypes in comparison with the other amides and ureas. Most of the synthesized compounds displayed a weak MT 2 selectivity except 6b and 6c. Furthermore, no noticeable difference in terms of binding affinities was observed between naphthofuran isomers 1 and 2. (1-Formyl-7-methoxynaphthalen-2-yloxy)acetonitrile (8). To a solution of 2-hydroxy-7methoxy-naphthalene-1-carbaldehyde (7) (10.11 g, 50 mmol) in acetone (230 mL) were added K 2 CO 3 (13.82 g, 100 mmol) and bromoacetonitrile (4.53 mL, 65 mmol). The mixture was stirred at reflux for 5 h. After filtration and evaporation of the filtrate, the residue was partitioned between CH 2 Cl 2 and water. The organic layer was washed with water, dried over for synthesis of amides 3a-c, 6a-b, 10a-b and 15a-b . To a solution of corresponding amine 3, 6, 10 or 15 (1 mmol) in EtOAc (30 mL) and water (10 mL) were added K 2 CO 3 (3 mmol) and the corresponding acid chloride (1.5 mmol) at 0 °C. The mixture was stirred at room temperature during 2 h and the layers were separated. The organic one was washed with a 1M solution of HCl and water, dried over MgSO 4 , filtered and concentrated under reduced pressure. N-((8-Methoxynaphtho[2,1-b]furan-1-yl) 88, 158.96, 154.11, 143.79, 130.93, 129.55, 126.21, 125.70, 120.40, 119.38, 116.84, 110.52, 103.32, 55.80, 34.51, 23 N-((8-Methoxynaphtho[2,1-b]furan-1-yl) 173.33, 158.59, 154.18, 143.97, 130.87, 129.49, 126.13, 125.80, 120.47, 119.22, 116.91, 110.60, 103.49, 55.69, 34.63, 13.96, 6.78 (2C) ; IR (υ, cm -1 , KBr) : 3282 (NH), 1632 (CO) ; LC-MS : m/z = 296 (MH + ). ((8-Methoxynaphtho[2,1-b]furan-1-yl) 158.57, 154.06, 143.65, 130.82, 129.58, 126.09, 125.67, 119.51, 116.71, 110.50, 103.52, 103.34, 55.74, 34.32, 34.22, 20 .05 (2C); IR (υ, cm -1 , KBr): 3296 (NH), 1636 (CO); LC-MS: m/z = 298 (MH + ). (2-(8-Methoxynaphtho[2,1-b]furan-1-yl) 85, 158.50, 153.80, 142.30, 131.03, 129.80, 125.86, 125.63, 120.61, 119.69, 116.22, 110.58, 103.17, 55.79, 39.28, 25.85, 23.07 ; IR (υ, cm -1 , KBr) : 3296 (NH), 1628 (CO) ; LC-MS : m/z = 284 (MH + ). (2-(8-Methoxynaphtho[2,1-b]furan-1-yl) 173. 18, 158.55, 153.86, 142.39, 131.10, 129.84, 125.96, 125.77, 120.63, 119.82, 116.29, 110.61, 103.20, 55.80, 39.28, 26.00, 14.18, 6.68 (2C) ; IR (υ, cm -1 , KBr) : 3288 (NH), 1634 (CO) ; LC-MS : m/z = 310 (MH + ). Methoxynaphtho[2,1-b 1, 158.3, 152.9, 152.8, 130.3, 128.9, 125.3, 125.0, 122.7, 116.5, 109.6, 103.4, 102.6, 55.4, 37.2, 23.2 ; IR (υ, fluoroacetate (32 mmol) . The mixture was refluxed during 12 h then, hydrolyzed and extracted with Et 2 O. The organic layer was washed with a 1M solution of HCl and water, dried over MgSO 4 , filtered and concentrated under reduced pressure. -N-((8-methoxynaphtho[2,1-b]furan-1-yl) (d, 1H, 9.0 Hz), 7.77 (d, 1H, 9.0 Hz), 7.60 (d, 1H, 9.0 Hz), 7.48 (d, 1H, 2.6 Hz), 7.12 (dd, 1H, 9.0 Hz and 2.6 Hz), 4.90 (d, 2H, 37.8 Hz) 7.84 (d, 1H, 9.0 Hz), 7.66 (d, 1H, 9.0 Hz), 7.48 (d, 1H, 9.0Hz), 7.38 (d, 1H, 2.7 Hz), 7.14 (dd, 1H, 9. 9, 154.8, 152.8, 131.0, 129.4, 125.7, 125.4, 123.5, 117.3, 110.4, 104.1, 104.0, 80.9 (d, J C-F (d, 1H, 9.0 Hz), 7.68 (d, 1H, 9.0 Hz), 7.63 (d, 1H, 2.4 Hz), 7.54 (d, 1H, 9.0 Hz), 7.30 (s, 1H), 7.12 (dd, 1H, 9.0 Hz and 2.4 Hz) , 6.74 (br s, 1H), 5.73 (br s, 2H), 4, 42 (d, 2H, 5.7 Hz) , 3.93 (s, 3H) ; 13 C NMR (300 MHz, DMSO-d 6 ) δ : 159.0, 158.4, 156.5, 152.3, 130.6, 129.0, 125.3, 124.8, 123.2, 116.8, 110.0, 103.5, 102.8, 55.9, 37.4 ; IR (υ, N 1 -((8-Methoxynaphtho[2,1-b]furan-2-yl) 4, 156.6, 152.3, 130.6, 129.0, 125.3, 124.8, 123.2, 116.8, 110.0, 103.5, 102.8, 55.9, 37.5, 26.9 158.6, 156.9, 152.7, 131.0, 129.4, 125.7, 125.2, 123.6, 117.2, 110.4, 104.0, 103.2, 56.3, 37.8, 35.1, 16.5 ; IR (υ,  3, 156.4, 152.3, 130.6, 128.8, 125.3, 124.3, 123.5, 116.7, 110.0, 103.5, 102.9, 55.8, 38.4, 34.5, 29.9, 16. N 3 -((8-methoxynaphtho[2,1-b ]furan-2-yl)methyl)thiourea (10i). Recrystallized from toluene (72%) as a white solid ; mp 185-186 °C ; 1 H NMR (300 MHz, DMSO-d 6 ) δ :
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in PBS containing EDTA 2 mM and centrifuged at 1000 x g for 5 min (4 °C). The resulting pellet was suspended in TRIS 5 mM (pH 7.5), containing EDTA 2 mM and homogenized using a Kinematica polytron. The homogenate was then centrifuged (95 000g, 30 min, 4 °C) and the resulting pellet suspended in 75 mM TRIS (pH 7.5), 12.5 mM MgCl 2 and 2 mM EDTA. Aliquots of membrane preparations were stored at -80 °C until use. 
